我国创新药物国家医保目录准入情况研究  

Study on Medicare Directory Access System for Innovative Drugs in China

作　　者：徐伟[1] 白婕[1] 

机构地区：[1]中国药科大学国际医药商学院,南京211198

出　　处：《中国药房》2016年第33期4609-4612,共4页China Pharmacy

基　　金：国家自然科学基金资助项目(No.71273278)

摘　　要：目的:为完善我国创新药物国家医保目录准入机制提供参考。方法:以创新药物进入《国家基本医疗保险、工伤保险和生育保险药品目录》(以下简称《医保目录》现状为切入点,考察我国医保制度对创新药物的政策支持度,通过描述性统计及制度比较法,对进入我国《医保目录》中的一类新药的数量、等待审批时间进行分析,并与其他国家进行比较,进而提出相应的政策建议。结果与结论:我国创新药物进入《医保目录》种类少(只占同期批准上市一类新药的20.17%)、等待审批时间长(进入目录的平均等待审批时间为935天)。药品遴选方式欠妥、静态的目录调整机制及相关政策间缺乏联动机制是造成上述现象的主要原因。OBJECTIVE： To provide reference for improving medicare drug directory access system for innovative drugs in Chi- na. METHODS： With entry point of the current status of innovative drugs entering National Basic Medical Insurance, Work lnjung Insurance and Maternity Insurance Drug System（Medicare Directcry）, the support degree of medicare system for policy of innova- tive drugs in China was studied, descriptive statistics and comparative method were conducted to analyze the numbers and waiting time of the grade 1 drugs in Medicare Directory and compare with other countries to provide corresponding policy recommenda- tions. RESULTS ＆ CONCLUSIONS： The innovative drugs in China suffered from less quantity （only accounted 20.17% to the new drugs approved for marketing over the same period） and long waiting time （the average waiting time of 935 days for entering the directory）. Inappropriate selection method, static adjustment mechanism of medicare drug directory and the lack of collabora- tion of policy were the main causes.

关 键 词：创新药物 医保目录 准入 

分 类 号：R95[医药卫生—药学]